Roots Analysis Identifies Top 5 CDx Development Companies
Roots Analysis has identified five companies offering comprehensive companion diagnostic (CDx) development services. These firms aid in identifying biomarkers crucial for drug efficacy and safety.
Market research firm Roots Analysis has released a list of the top five companies specializing in companion diagnostics (CDx) development. These organizations provide end-to-end services to support drug development, helping to identify patients most likely to benefit from specific therapies and those at higher risk for adverse side effects.
A companion diagnostic is an in vitro diagnostic device that provides crucial information for the safe and effective use of a compatible drug or biologic. The process involves identifying, validating, and testing for suitable biomarkers in biological samples. Due to the complexity, drug developers often outsource this phase to specialized service providers.
Roots Analysis evaluated over 155 CDx development companies. The top five identified are BGI Genomics, Eurofins, Labcorp, Q2 Solutions, and Quest Diagnostics. The selection was based on service portfolio strength and geographic reach.
BGI Genomics, one of the companies listed, recently established a new clinical laboratory in Uruguay to facilitate early disease diagnosis. The company offers integrated genomic sequencing and proteomics services globally, utilizing its proprietary DNBseq technology.